A study published in the *Liver Transplantation* journal reveals that a new proactive treatment protocol developed by Mayo Clinic researchers has led to a remarkable 0% heavy alcohol relapse rate among liver transplant patients, compared to a historical relapse rate of around 25%. This study involved 21 patients who adhered to the protocol, which combines anticraving medication, regular follow-ups, alcohol metabolite testing, and coordinated care from a multidisciplinary team. Heavy alcohol use is defined as binge drinking or consuming alcohol more than four days a week, which poses significant health risks, especially post-transplant. Alcohol-associated liver disease is now the primary reason for liver transplants in the U.S., emphasizing the need for effective relapse prevention strategies. The researchers hope that these findings will reshape addiction treatment approaches in transplant centers nationwide and reduce stigma surrounding alcohol use disorder. Dr. Channa Jayasekera, a senior author of the study, notes that larger studies are needed to confirm these results and further validate the protocol's effectiveness.